Skip to Content
Merck
CN

934356

Val-cit-PAB-OH

≥95%

Synonym(s):

L-Valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethylphenyl]-L-ornithinamide, L-Valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H29N5O4
CAS Number:
Molecular Weight:
379.45
UNSPSC Code:
12352200
NACRES:
NA.21
MDL number:
Assay:
≥95%
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

assay

≥95%

form

powder

storage temp.

2-8°C

SMILES string

N([C@@H](CCCNC(=O)N)C(=O)Nc1ccc(cc1)CO)C(=O)[C@@H](N)C(C)C

InChI

1S/C18H29N5O4/c1-11(2)15(19)17(26)23-14(4-3-9-21-18(20)27)16(25)22-13-7-5-12(10-24)6-8-13/h5-8,11,14-15,24H,3-4,9-10,19H2,1-2H3,(H,22,25)(H,23,26)(H3,20,21,27)/t14-,15-/m0/s1

InChI key

VEGGTWZUZGZKHY-GJZGRUSLSA-N

Application

This is a cathepsin cleavable linker used in the construction of antibody drug conjugates (ADC).

Cathepsin cleaveable linkers


Storage Class

11 - Combustible Solids

wgk

WGK 3

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Qinhuai Lai et al.
European journal of medicinal chemistry, 199, 112364-112364 (2020-05-14)
Cryptophycin-52 (CR52), a tubulin inhibitor, exhibits promising antitumor activity in vitro (picomolar level) and in mouse xenograft models. However, the narrow therapeutic window in clinical trials limits its further development. Antibody-drug conjugate (ADC), formed by coupling cytotoxic compound (payload) to an
Zixuan Ye et al.
International journal of nanomedicine, 16, 2443-2459 (2021-04-06)
Specific modifications to carriers to achieve targeted delivery of chemotherapeutics into malignant tissues are a critical point for efficient diagnosis and therapy. In this case, bovine serum albumin (BSA) was conjugated with cetuximab-valine-citrulline (vc)-doxorubicin (DOX) to target epidermal growth factor



Global Trade Item Number

SKUGTIN
934356-100MG04065270182784
934356-50MG04065270182791